Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The A9 subtype ventral midbrain dopaminergic neurons are specialized neurons located in the substantia nigra pars compacta of the midbrain. They are responsible for the majority of dopamine production that regulates motor control, motivation, and reward-related behaviors. Degeneration of these neurons is the primary cause of dopamine deficiency in Parkinson’s disease. Restoration of dopamine production through the differentiation and transplantation of stem-cell-derived A9 dopaminergic neurons is a promising therapeutic strategy for treating Parkinson's disease and related disorders. The success of this approach depends on accurately generating and grafting these specific neuron subtypes, as they uniquely innervate the dorsolateral striatum and are essential for effective motor recovery[1][3][4][5][6].
Replacement of lost dopaminergic neurons to restore dopamine production; Restoration of nigrostriatal pathway function; Direct neurotransmitter supplementation (indirect, via drugs)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on A9 subtype ventral midbrain dopaminergic neuron.